Efficacy and safety of the CDK4/6 inhibitor palbociclib during different lines of treatment in patients with advanced stage endocrine sensitive/HER2 negative breast cancer.

被引：1
|
作者：
Zurcher, Jean-Philippe
Aedo, Veronica
Stravodimou, Athina
Sarivalasis, Apostolos
Zaman, Khalil
机构：
[1] Univ Hosp CHUV, Dept Oncol, Lausanne, Switzerland
[2] Univ Hosp CHUV, Breast Ctr, Lausanne, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e13052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13052
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
    Bao, Kelvin K. H.
    Sutanto, Leone
    Tse, Shirley S. W.
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Pre-clinical analysis of the CDK4/6 inhibitor palbociclib in HER2-positive breast cancer.
    ElChaarani, Bilal
    Stires, Hillary
    Pohlmann, Paula Raffin
    Riggins, Rebecca
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Palbociclib, a CDK4/6 inhibitor, suppresses proliferation of triple negative breast cancer
    Min, Ahrum
    Kim, Yu Jin
    Hang, Hyemin
    Lim, Jee Min
    Kim, Seongyeong
    Kim, So Hyeon
    Suh, Koung Jin
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Im, Seock-Ah
    CANCER RESEARCH, 2018, 78 (13)
  • [4] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Kashiwagi, Shinichiro
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Takashima, Tsutomu
    Morisaki, Tamami
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [5] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Asano, Yuka
    Kashiwagi, Shinichiro
    Goto, Wataru
    Takahashi, Katsuyuki
    Takashima, Tsutomu
    Noda, Satoru
    Onoda, Naoyoshi
    Tomita, Shuhei
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [6] Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience
    Chawla, Sumir
    Hill, Alison
    Fearfield, Louise
    Johnston, Stephen
    Parton, Marina
    Heelan, Kara
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (02) : 535 - 545
  • [7] Safety and Efficacy of Palbociclib (CDK4/6 inhibitor) and Radiotherapy in Metastatic Breast Cancer Patients: Initial Results of a Novel Combination
    Chowdhary, M.
    Sen, N.
    Chowdhary, A.
    Usha, L.
    Cobleigh, M.
    Wang, D.
    Patel, K.
    Barry, P. N., Jr.
    Rao, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E2 - E2
  • [8] Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience
    Sumir Chawla
    Alison Hill
    Louise Fearfield
    Stephen Johnston
    Marina Parton
    Kara Heelan
    Breast Cancer Research and Treatment, 2021, 188 : 535 - 545
  • [9] The Effects of HER2 on CDK4/6 Activity in Breast Cancer
    Sinclair, William D.
    Cui, Xiaoyan
    CLINICAL BREAST CANCER, 2022, 22 (03) : E278 - E285
  • [10] CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
    Zhang, Kai
    Hong, Ruoxi
    Kaping, Lee
    Xu, Fei
    Xia, Wen
    Qin, Ge
    Zheng, Qiufan
    Lu, Qianyi
    Zhai, Qinglian
    Shi, Yanxia
    Yuan, Zhongyu
    Deng, Wuguo
    Chen, Miao
    Wang, Shusen
    CANCER LETTERS, 2019, 447 : 130 - 140
12345